AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05201300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
Study NCT06522139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Episealer Talus Implant
Description: Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
Study NCT05042856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PanOptix IOL implantation
Description: All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
Study NCT05228314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Study NCT04666220 — intervention group
Intervention type: OTHER
Intervention: VETC evaluation
Description: We will evaluate VETC presence on tissue specimens
Study NCT05242380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell Exercise
Description: The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row.
Study NCT06266832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study NCT06266832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, ivgtt, d1, Q3W
Study NCT06266832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, po, bid, d1-14, Q3W
Study NCT06266832 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Radiation
Description: Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
Study NCT06266832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
Study NCT05903768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)
Study NCT05903768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax capsular stretching
Description: Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times.
Study NCT04772612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib
Study NCT06415136 — intervention group
Intervention type: DEVICE
Intervention: SeaSpine Shoreline
Description: The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
Study NCT06252688 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.
Description: All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)
Study NCT04799093 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EyeBOX
Description: Eye-Tracking based diagnostic
Study NCT05263778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic Acid / Ezetimibe Oral Tablet
Description: Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
Study NCT05263778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo by mouth once daily for 12 weeks
Study NCT04372940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Irrigation
Description: Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
Study NCT04372940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Irrigation
Description: Saline will serve as the control.
Study NCT06254885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Equi-crestal Implant placement
Description: A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.
Study NCT06254885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-crestal Implant placement
Description: A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
Study NCT05866809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-660S
Description: Administered orally
Study NCT05866809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06445270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDM Prevention Program
Description: Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
Study NCT06519851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%
Description: postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
Study NCT06519851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interscalene block with 20 ml bupivacaine 0.25%
Description: postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
Study NCT05179356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin 10 mg given once daily for three months
Study NCT05179356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04440865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genius® System-assisted Colonoscopy
Description: Genius® Intelligence System is used to assist Colonoscopy
Study NCT04440865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy without Genius® Intelligence System is performed
Study NCT05985369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet and resistance exercise
Description: Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
Study NCT05298449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU-045
Description: HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder
Study NCT05298449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study NCT05171556 — intervention group
Intervention type: OTHER
Intervention: Cosmetic product
Description: RV4942A is a face balm product
Study NCT06091683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Description: Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy.
Study NCT04784572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: first injection delay and second injection delay
Description: During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance.
Study NCT05346068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPN™ NCB Super High Pressure PCI Balloon
Description: In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion.
Study NCT05346068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave™ C2 IVL Catheter
Description: In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion.
Study NCT05115149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIBRAINT RehUp robotic orthosis
Description: VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
Study NCT05115149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tSCS during the exercise
Description: During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz.
Study NCT05115149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tSCS prior to the exercise
Description: Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz.
Study NCT05115149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neostim-5
Description: Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
Study NCT05115149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
Study NCT05228314 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Study NCT05228314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squalene based adjuvant
Description: Squalene based adjuvant
Study NCT06057467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Agents
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
Study NCT06057467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Agents
Description: Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
Study NCT05986396 — intervention group
Intervention type: DEVICE
Intervention: INSPIRIS Resilia (model 11500A)
Description: Aortic Valve
Study NCT04919798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bladder emptying device
Description: The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
Study NCT05940090 — intervention group
Intervention type: DEVICE
Intervention: SkinIO
Description: The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
Study NCT05243732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Music Listening
Description: Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness.
Study NCT05243732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given
Study NCT05959356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Envafolimab + mFOLFOXIRI
Description: Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Study NCT05959356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + mFOLFOX6/FOLFIRI
Description: Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Study NCT05741619 — intervention group
Intervention type: OTHER
Intervention: Long-term outcome
Description: Autonomy, physical examination, behavioural disorders
Study NCT05083286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Injection of glabellar rhytids
Study NCT06072456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic lateral suspension
Description: Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
Study NCT06072456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic pectopexy
Description: Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
Study NCT06072456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Description: Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
Study NCT06518018 — intervention group
Intervention type: RADIATION
Intervention: HDR brachytherapy (30Gy single fraction)
Description: Study Group receives a novel triple combination therapy for advanced NSCLC in the second-line setting. The treatment begins with a single fraction of high-dose rate (HDR) brachytherapy, delivering 30 Gy locally to the tumor site. This is followed within 1-3 days by systemic therapy, combining immunotherapy and chemotherapy , both administered intravenously.
Study NCT06518018 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
Study NCT06176911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
Study NCT06176911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: 200 mg twice daily.
Study NCT06176911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: 200 mg twice daily.
Study NCT05275504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Study NCT05228314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CpG/alum adjuvant
Description: CpG/alum adjuvant
Study NCT05228314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CpG/alum adjuvant
Description: CpG/alum adjuvant